Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
Trackers› Clinical trials› Symptomatic Hypertrophic Cardiomyopathy (HCM)
Clinical trial register · Italy

Symptomatic Hypertrophic Cardiomyopathy (HCM) Trials in Italy, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Italy and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 6788 matching records held by the registry are in this view. Synced 13 Nov 2026, 03:19 UTC
6788
Studies in scope
all four open statuses
4077
Recruiting now
open to new participants
1016
Lead sponsors
across recruiting studies
Top sites
Florence 1 Milan 1 Naples 1 Pisa 1 Roma 1
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Cytokinetics1
Site location
Florence1 Milan1 Naples1 Pisa1 Roma1 Trieste1
All 6 locations
Target enrolment
to

Symptomatic Hypertrophic Cardiomyopathy (HCM) trials in Italy

1 of 6788 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Italy
Start
By invitation
Cytokinetics
Phase 2/3
900
Florence, Milan, Naples, Pisa, Roma, Trieste
2021-05-06
Rows per page Showing 1–1 of 1
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Italian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 17 November 2026. https://priyalifescience.com/clinical-trials-italy/condition/symptomatic-hypertrophic-cardiomyopathy-hcm

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Italy and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 6,788 studies in total at the last sync on 13 Nov 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1 of those studies listing the condition Symptomatic Hypertrophic Cardiomyopathy (HCM).

How many Symptomatic Hypertrophic Cardiomyopathy (HCM) trials are recruiting in Italy?

0 of the 1 studies on this page are recruiting new participants as of the 13 Nov 2026, 03:19 UTC sync. A further 0 have not yet opened recruitment, 0 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Symptomatic Hypertrophic Cardiomyopathy (HCM)), 1 studies
PhaseStudiesRecruitingShare
Phase 2/310100%

Most active sponsors

Lead sponsors with the most studies (Symptomatic Hypertrophic Cardiomyopathy (HCM))
Lead sponsorStudiesRecruiting
Cytokinetics10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.